Filgotinib, administred at 200 mg once daily, is a selective, ATP-competitive JAK1 inhibitor approved in September 2020 by the EMA and in Japan for treating moderate to severe rheumatoid arthritis in adults. This evidence concerns the gene JAK1 and rheumatoid arthritis.